GTC Biotherapeutics (fka GTCB)

[keitern]

Since GTCB competes with potential partners, they may feel it is too risky to allow GTCB to do the trials.

Conjecture: GTCB is trying to have their cake and eat it; they want to leverage their platform but want to own some proteins too (or 50% of it as in the LFB case). This competitive stance may limit their ability to partner up with other protein producers solely to leverage their superior production platform. Others may feel this gives GTCB too much access to their IP. I have no problem with this if true, I am just trying to understand how this all fits.